Ian Schofield

Ian Schofield

Ian Schofield has been writing on issues affecting the pharmaceutical and biotech industry since the mid-1980s. He writes for Scrip and Pink Sheet and can be contacted at ian.schofield@informa.com.

Recent posts

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing... Read more »

Page 1 of 1

Underwriters and Partners

Xconomy Insight

Sponsored · Webinar
July 21 – The Need for Manufacturing Execution Systems (MES) in Cell and Gene Therapy
A discussion on business drivers, technical considerations, special requirements of cell and gene product manufacturing & digitization strategy
Global OT/IT Quality Services

Sponsored · Whitepaper
Potency Assay Development for Cell and Gene Therapy Products
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Xconomy on Demand

We offer a number of ways to subscribe for free!